Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

"Our focus is working with Eisai to obtain FDA approval of lorcaserin, preparing to submit an application for European approval of lorcaserin, and advancing select earlier-stage research and development programs on our own or in collaboration," said Jack Lief, Arena's President and Chief Executive Officer. "Resubmitting the lorcaserin NDA is our top priority, and we are committed to addressing the outstanding issues to the FDA's satisfaction."

Arena reported a net loss in the fourth quarter of 2010 of $28.2 million, or $0.23 per share, compared to a net loss in the fourth quarter of 2009 of $29.8 million, or $0.32 per share, and a net loss in the full year ended December 31, 2010, of $124.5 million, or $1.14 per share, compared to a net loss in the full year ended December 31, 2009, of $153.2 million, or $1.82 per share.

Research and development expenses continued to decline to $16.5 million in the fourth quarter of 2010 from $21.2 million in the fourth quarter of 2009. Research and development expenses declined to $75.5 million in the full year ended December 31, 2010, from $110.2 million in the full year ended December 31, 2009. This decrease is primarily due to the completion of Arena's lorcaserin Phase 3 clinical trials. Arena expects its research and development expenses to continue to decline in 2011 due to the completion of the lorcaserin Phase 3 clinical trials, expected cost savings from its recently announced workforce reduction and other cost-containment measures. Research and development expenses for all of 2010 included $3.4 million in non-cash, share-based compensation expense, compared to $4.1 million in 2009. General and administrative
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The American Association for Homecare (AAHomecare) is ... has joined the AAHomecare Corporate Partner Program. ... have been actively involved in AAHomecare for much of ... grown into a major global manufacturer of home medical ... to increase efforts on behalf of the HME sector ...
(Date:9/19/2014)... 2014 Larry J. Merlo , President and ... speak before the National Press Club in Washington, ... move to stop selling tobacco products and its leadership in ... "Dramatic changes in our health care system pose ... Merlo has said. "CVS Health has a truly unique combination ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... , BEDFORD, Ohio , Jan. 14 ... is pleased to announce FDA approval for the addition of ... line. This product is AP rated and is equivalent to ... for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated ...
... , , BETHLEHEM, Pa. , Jan. 13 ... and easy-to-use WHIN ® Safe Huber Needle , an implantable ... a single Huber Needle and provides clinicians with advanced protection ... http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) , There are three models of the WHIN ® ...
Cached Medicine Technology:Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 2Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 3Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 4B. Braun Introduces WHIN(R) Safe Huber Needle 2B. Braun Introduces WHIN(R) Safe Huber Needle 3B. Braun Introduces WHIN(R) Safe Huber Needle 4
(Date:9/20/2014)... Increases in household, construction and ... treatment volumes. However, government regulations and higher landfill ... According to IBISWorld industry analyst Alen Allday, “over ... at reducing the volume of waste generated, and ... Still, a large proportion of waste generated by ...
(Date:9/20/2014)... York (PRWEB) September 20, 2014 ... to grow in federal court, Bernstein Liebhard LLP ... Drug Administration (FDA) have voted overwhelmingly to recommend ... in men be subjected to further study in ... a report published on September 18th by Bloomberg.com, ...
(Date:9/20/2014)... Sept. 20, 2014 (HealthDay News) -- As flu season ... infection is to get a flu shot and a ... A primary care doctor can vaccinate people against the ... patients may have. Retail stores may provide flu shots ... advice, said Dr. Jorge Parada, medical director of infection ...
(Date:9/20/2014)... New York (PRWEB) September 20, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries ... yet another insurer has announced plans to end ... posted on its website last month, Harrisburg, Pennsylvania-based ... effective November 1, 2014. The insurer said its ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee and ... re-visiting that advice and changing his stance after considering two ... on oral health. “There’s good news and great news,” says ... in protecting against gum disease, and red wine can help ... from the September 2014 issue of Boston University School ...
Breaking Medicine News(10 mins):Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3
... Breakthroughs in the Field , , ... and the American Friends of The Hebrew University ... co-chair of the Bill & Melinda Gates Foundation, with its inaugural ... New York Hilton. , , ...
... MEXICO CITY and PRINCETON, N.J., Dec. 5 MetLife ... life insurance company in Mexico, and a leading provider ... today that it has partnered with Assist America, Inc., ... through employee benefit plans, to protect 500,000 of its ...
... soon be possible, thanks to a discovery made by ... Coastal Health Research Institute neuroscience researchers. , The researchers ... previously found to that cause cell death following a ... following head trauma or a stroke. , The findings, ...
... A Better Tomorrow, a fast growing,Southern California-based rehabilitation center, is ... and the United,States. , ... for their,addictions," said Sylvia Reynolds, a bilingual therapist from A ... "And these calls are ...
... and Families Embrace Life to the Fullest , ... a world-leading developer and marketer of innovative medical technologies for ... the new global lifestyle magazine for people with an ostomy. ... articles on living a healthy and active life after ostomy ...
... Anthem Blue Cross and Blue Shield,in New Hampshire has ... the current issue of U.S. News & World Report/NCQA America,s ... best health plans,is the result of outstanding overall performance in ... Anthem Blue Cross and Blue Shield ...
Cached Medicine News:Health News:Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem 2Health News:Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem 3Health News:MetLife Mexico Life Insurance Company Partners with Assist America for Global Emergency Medical Assistance Services 2Health News:New target discovered to treat epileptic seizures following brain trauma or stroke 2Health News:Southern California Rehabilitation Clinic is Hiring Bilingual Therapists to Better Serve the Hispanic Communities of Mexico and the United States 2Health News:ConvaTec Launches New Lifestyle Magazine for People With an Ostomy 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List 3
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad selection ... a wide variety of ophthalmic procedures. ... sterile, complete with a safety cap ... " position when not in use, ...
... The B-VAT® PC visual acuity system ... features of the B-VAT II. The system ... sequencing, contrast sensitivity testing and animated characters. ... the operator has single letter, single line ...
Medicine Products: